Hemagen Diagnostics (HMGN) Stock Price, News & Analysis

Company Overview

Hemagen Diagnostics, Inc. is a developer, manufacturer and marketer of in vitro diagnostic products designed for blood screening, infectious disease testing and molecular diagnostics. Through its portfolio of immunoassays, nucleic acid amplification tests and specialty diagnostic kits, the company aims to support blood banks, reference laboratories and clinical research organizations in detecting biomarkers and pathogens with high sensitivity and specificity.

The company’s product range includes enzyme-linked immunosorbent assay (ELISA) kits, rapid diagnostic tests and molecular diagnostic reagents used for screening of transfusion-transmitted infections, emerging infectious diseases and genetic markers. Hemagen Diagnostics leverages proprietary technology platforms to develop assays that can be performed manually or on automated analyzers, catering to diverse laboratory workflows. In addition, the company offers custom assay development services and technical support to help customers integrate new tests into their operations.

Hemagen Diagnostics primarily serves markets in North America, Europe and the Asia-Pacific region through a network of direct sales representatives, distributors and strategic partnerships. Its customer base includes commercial and hospital laboratories, government agencies and research institutions. With an ongoing focus on research and development, the company seeks to expand access to reliable diagnostic tools and address evolving public health needs.

Key Stats

• Today's Range: $0.0002 to $0.0002
• 50-Day Range: N/A
• 52-Week Range: $0.00 to $0.13
• Volume: N/A
• Average Volume: 33 shs
• Market Capitalization: N/A
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

Company Calendar

• Today: 8/05/2026
• Fiscal Year End: 9/30/2026

Industry, Sector and Symbol

• Stock Exchange: OTCMKTS
• Sector: Healthcare
• Industry: Healthcare Equipment & Supplies
• Sub-Industry: N/A
• Current Symbol: OTCMKTS:HMGN
• CIK: N/A
• Web: www.hemagen.com
• Phone: (443) 367-5500
• Fax: 443-367-5527
• Employees: 15
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: N/A
• Free Float: N/A
• Market Cap: N/A
• Optionable: Not Optionable
• Beta: 20.54